Share Price and Basic Stock Data
Last Updated: December 12, 2025, 7:12 pm
| PEG Ratio | -0.62 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Ambalal Sarabhai Enterprises Ltd operates primarily in the pharmaceutical sector, a domain that has shown resilience despite economic fluctuations. The company reported a market capitalization of ₹203 Cr and a current share price of ₹26.5. Over the last fiscal year, the revenue figures have displayed some volatility, with sales standing at ₹170 Cr for FY 2023, a slight dip from ₹197 Cr in FY 2022. However, the latest quarterly results indicate a potential rebound, with sales rising to ₹54.35 Cr in March 2024, suggesting that the company may have turned a corner. Notably, the operating profit margin (OPM) has fluctuated significantly, with a peak of 7.54% in March 2023 but dipping to -11% in June 2023, highlighting the challenges in managing costs amidst changing market dynamics. The latest quarterly sales figures reflect a gradual recovery, with ₹40.01 Cr recorded in September 2023, reinforcing the notion that the company is working towards stabilizing its revenue streams.
Profitability and Efficiency Metrics
When delving into profitability, Ambalal Sarabhai’s metrics reveal a mixed picture. The return on equity (ROE) stood at 6.25%, which, while positive, may appear modest when compared to industry leaders. The net profit for FY 2023 was reported at ₹13 Cr, translating to an earnings per share (EPS) of ₹1.45, but this figure declined to ₹0.64 in FY 2025, indicating a downward pressure on profitability. The interest coverage ratio (ICR) is relatively robust at 4.56x, suggesting that the company is comfortably covering its interest obligations. However, the operating profit margin remains a point of concern, reported at just 3.62% for the latest fiscal year. This figure illustrates ongoing challenges in controlling operational costs, especially in a sector where margins can be tight. The cash conversion cycle, which has been consistently negative, indicates efficient working capital management, but the overall profitability metrics suggest a need for strategic operational improvements.
Balance Sheet Strength and Financial Ratios
Examining the balance sheet, Ambalal Sarabhai appears to be in a relatively stable position, with total borrowings reported at ₹47 Cr against reserves of ₹71 Cr. This indicates a favorable capital structure, with a debt-to-equity ratio of 0.34, suggesting that the company is not over-leveraged. The current ratio, however, is slightly below 1 at 0.98, reflecting a potential liquidity concern. This means that while the company can meet its short-term obligations, it may not have a significant buffer. The book value per share has steadily increased to ₹18.27, enhancing shareholder value over time. With a price-to-book value (P/BV) ratio of 1.92x, the stock seems to be trading at a premium, which could be a signal of investor confidence or a risk of overvaluation. The return on capital employed (ROCE) at 9.12% indicates that the company is generating reasonable returns on its investments, but there is still room for improvement in efficiency and capital utilization.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Ambalal Sarabhai reveals a strong public presence, with 68.32% of shares held by retail investors. This widespread ownership can be a double-edged sword; on one hand, it indicates a broad base of support, while on the other, it may reflect a lack of institutional backing, as foreign institutional investors (FIIs) hold only 0.34% and domestic institutional investors (DIIs) hold none. The promoter holding stands at 31.35%, which aligns with norms for corporate governance, but the absence of institutional investment could raise questions about long-term strategic support. The number of shareholders has gradually decreased, reflecting potential disenchantment among smaller investors or simply consolidation in ownership. This trend could be a concern, as a dwindling shareholder base might indicate reduced confidence in the company’s future prospects. The stability of the promoter stake, however, can provide some reassurance to investors.
Outlook, Risks, and Final Insight
Looking ahead, investors in Ambalal Sarabhai need to weigh both opportunities and risks carefully. The potential for revenue recovery is promising, especially with recent quarterly improvements, but the company must address its profitability challenges head-on. The pharmaceutical sector is highly competitive, and the ability to maintain margins while managing costs will be critical. Moreover, the lack of institutional investment may limit the company’s growth prospects and market perception. Risks such as fluctuating raw material costs, regulatory challenges, and market competition could impact profitability. Investors should consider these factors when evaluating the stock. The balance sheet appears solid, but liquidity concerns could pose short-term risks. For those considering an investment, a deep dive into operational strategies and market positioning will be essential in assessing whether Ambalal Sarabhai can navigate its challenges and capitalize on its strengths in the evolving pharmaceutical landscape.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 146 Cr. | 116 | 239/84.3 | 32.3 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,249 Cr. | 390 | 479/192 | 88.0 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 33.1 Cr. | 44.6 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 44.0 Cr. | 30.1 | 31.0/17.0 | 105 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,474.87 Cr | 1,156.59 | 51.98 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 43.65 | 46.84 | 35.36 | 44.44 | 36.10 | 40.01 | 43.11 | 54.35 | 40.70 | 44.70 | 45.97 | 64.81 | 40.34 |
| Expenses | 42.91 | 46.11 | 33.79 | 41.09 | 40.07 | 39.00 | 40.58 | 49.70 | 40.23 | 42.16 | 46.67 | 59.51 | 38.88 |
| Operating Profit | 0.74 | 0.73 | 1.57 | 3.35 | -3.97 | 1.01 | 2.53 | 4.65 | 0.47 | 2.54 | -0.70 | 5.30 | 1.46 |
| OPM % | 1.70% | 1.56% | 4.44% | 7.54% | -11.00% | 2.52% | 5.87% | 8.56% | 1.15% | 5.68% | -1.52% | 8.18% | 3.62% |
| Other Income | 2.69 | 2.38 | 3.06 | 5.71 | 1.37 | 2.85 | 1.63 | 4.79 | 2.30 | 2.80 | 5.76 | -5.37 | 8.36 |
| Interest | 0.43 | 0.45 | 0.56 | 0.99 | 0.95 | 0.92 | 0.99 | 0.90 | 0.95 | 1.22 | 1.14 | 0.96 | 1.01 |
| Depreciation | 0.60 | 0.62 | 0.61 | 0.92 | 1.05 | 1.14 | 1.13 | 0.25 | 0.98 | 1.01 | 0.99 | 1.02 | 0.88 |
| Profit before tax | 2.40 | 2.04 | 3.46 | 7.15 | -4.60 | 1.80 | 2.04 | 8.29 | 0.84 | 3.11 | 2.93 | -2.05 | 7.93 |
| Tax % | 34.17% | 50.00% | 12.72% | 20.14% | 5.87% | 40.00% | 34.31% | -8.69% | 59.52% | 15.76% | 23.89% | -86.83% | -3.66% |
| Net Profit | 1.58 | 1.02 | 3.01 | 5.71 | -4.87 | 1.08 | 1.33 | 9.02 | 0.35 | 2.62 | 2.23 | -0.27 | 8.22 |
| EPS in Rs | 0.21 | 0.13 | 0.39 | 0.75 | -0.64 | 0.14 | 0.17 | 1.18 | 0.05 | 0.34 | 0.29 | -0.04 | 1.07 |
Last Updated: August 19, 2025, 11:55 pm
Below is a detailed analysis of the quarterly data for Ambalal Sarabhai Enterprises Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 40.34 Cr.. The value appears to be declining and may need further review. It has decreased from 64.81 Cr. (Mar 2025) to 40.34 Cr., marking a decrease of 24.47 Cr..
- For Expenses, as of Jun 2025, the value is 38.88 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 59.51 Cr. (Mar 2025) to 38.88 Cr., marking a decrease of 20.63 Cr..
- For Operating Profit, as of Jun 2025, the value is 1.46 Cr.. The value appears to be declining and may need further review. It has decreased from 5.30 Cr. (Mar 2025) to 1.46 Cr., marking a decrease of 3.84 Cr..
- For OPM %, as of Jun 2025, the value is 3.62%. The value appears to be declining and may need further review. It has decreased from 8.18% (Mar 2025) to 3.62%, marking a decrease of 4.56%.
- For Other Income, as of Jun 2025, the value is 8.36 Cr.. The value appears strong and on an upward trend. It has increased from -5.37 Cr. (Mar 2025) to 8.36 Cr., marking an increase of 13.73 Cr..
- For Interest, as of Jun 2025, the value is 1.01 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.96 Cr. (Mar 2025) to 1.01 Cr., marking an increase of 0.05 Cr..
- For Depreciation, as of Jun 2025, the value is 0.88 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.02 Cr. (Mar 2025) to 0.88 Cr., marking a decrease of 0.14 Cr..
- For Profit before tax, as of Jun 2025, the value is 7.93 Cr.. The value appears strong and on an upward trend. It has increased from -2.05 Cr. (Mar 2025) to 7.93 Cr., marking an increase of 9.98 Cr..
- For Tax %, as of Jun 2025, the value is -3.66%. The value appears to be increasing, which may not be favorable. It has increased from -86.83% (Mar 2025) to -3.66%, marking an increase of 83.17%.
- For Net Profit, as of Jun 2025, the value is 8.22 Cr.. The value appears strong and on an upward trend. It has increased from -0.27 Cr. (Mar 2025) to 8.22 Cr., marking an increase of 8.49 Cr..
- For EPS in Rs, as of Jun 2025, the value is 1.07. The value appears strong and on an upward trend. It has increased from -0.04 (Mar 2025) to 1.07, marking an increase of 1.11.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:59 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 105 | 124 | 132 | 134 | 125 | 150 | 133 | 163 | 197 | 170 | 173 | 196 | 196 |
| Expenses | 112 | 129 | 145 | 137 | 137 | 144 | 136 | 165 | 171 | 162 | 167 | 187 | 187 |
| Operating Profit | -7 | -4 | -13 | -3 | -12 | 6 | -3 | -2 | 25 | 8 | 6 | 9 | 9 |
| OPM % | -7% | -3% | -10% | -2% | -9% | 4% | -2% | -1% | 13% | 5% | 3% | 5% | 4% |
| Other Income | 2 | 13 | 95 | -2 | 25 | 8 | 24 | 40 | 33 | 12 | 10 | 5 | 12 |
| Interest | 11 | 10 | 4 | 5 | 3 | 3 | 4 | 3 | 2 | 3 | 6 | 5 | 4 |
| Depreciation | 3 | 5 | 17 | 4 | 2 | 2 | 3 | 2 | 2 | 3 | 4 | 4 | 4 |
| Profit before tax | -20 | -6 | 62 | -14 | 8 | 8 | 15 | 33 | 54 | 15 | 7 | 5 | 12 |
| Tax % | 3% | 13% | 22% | 34% | 84% | 48% | 6% | 10% | 13% | 25% | 15% | -2% | |
| Net Profit | -20 | -7 | 48 | -18 | 1 | 4 | 14 | 29 | 47 | 11 | 6 | 5 | 13 |
| EPS in Rs | -2.64 | -0.87 | 6.28 | -2.38 | 0.17 | 0.55 | 1.83 | 3.83 | 6.16 | 1.49 | 0.74 | 0.64 | 1.66 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 65.00% | 785.71% | -137.50% | 105.56% | 300.00% | 250.00% | 107.14% | 62.07% | -76.60% | -45.45% | -16.67% |
| Change in YoY Net Profit Growth (%) | 0.00% | 720.71% | -923.21% | 243.06% | 194.44% | -50.00% | -142.86% | -45.07% | -138.66% | 31.14% | 28.79% |
Ambalal Sarabhai Enterprises Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 8% |
| 3 Years: | 0% |
| TTM: | 10% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | -9% |
| 3 Years: | -37% |
| TTM: | 60% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 7% |
| 3 Years: | 1% |
| 1 Year: | -51% |
| Return on Equity | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 13% |
| 3 Years: | 7% |
| Last Year: | 6% |
Last Updated: September 5, 2025, 2:16 pm
Balance Sheet
Last Updated: December 10, 2025, 3:47 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 77 | 77 | 77 | 77 | 77 | 77 | 77 | 77 | 77 | 77 | 77 | 77 | 77 |
| Reserves | -79 | -86 | -38 | -51 | -50 | -46 | -32 | -3 | 43 | 54 | 60 | 63 | 71 |
| Borrowings | 42 | 46 | 47 | 42 | 43 | 40 | 31 | 28 | 27 | 45 | 46 | 51 | 47 |
| Other Liabilities | 128 | 132 | 94 | 93 | 128 | 144 | 111 | 108 | 84 | 70 | 67 | 79 | 66 |
| Total Liabilities | 167 | 169 | 180 | 160 | 197 | 214 | 186 | 210 | 231 | 246 | 250 | 270 | 260 |
| Fixed Assets | 94 | 91 | 72 | 72 | 59 | 58 | 57 | 57 | 58 | 85 | 88 | 87 | 87 |
| CWIP | 0 | 1 | 9 | 3 | 14 | 24 | 0 | 1 | 12 | 4 | 0 | 0 | 0 |
| Investments | 1 | 1 | 8 | 5 | 5 | 9 | 18 | 27 | 33 | 32 | 29 | 32 | 32 |
| Other Assets | 71 | 76 | 92 | 80 | 119 | 123 | 110 | 125 | 128 | 125 | 133 | 151 | 141 |
| Total Assets | 167 | 169 | 180 | 160 | 197 | 214 | 186 | 210 | 231 | 246 | 250 | 270 | 260 |
Below is a detailed analysis of the balance sheet data for Ambalal Sarabhai Enterprises Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 77.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 77.00 Cr..
- For Reserves, as of Sep 2025, the value is 71.00 Cr.. The value appears strong and on an upward trend. It has increased from 63.00 Cr. (Mar 2025) to 71.00 Cr., marking an increase of 8.00 Cr..
- For Borrowings, as of Sep 2025, the value is 47.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 51.00 Cr. (Mar 2025) to 47.00 Cr., marking a decrease of 4.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 66.00 Cr.. The value appears to be improving (decreasing). It has decreased from 79.00 Cr. (Mar 2025) to 66.00 Cr., marking a decrease of 13.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 260.00 Cr.. The value appears to be improving (decreasing). It has decreased from 270.00 Cr. (Mar 2025) to 260.00 Cr., marking a decrease of 10.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 87.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 87.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 32.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 32.00 Cr..
- For Other Assets, as of Sep 2025, the value is 141.00 Cr.. The value appears to be declining and may need further review. It has decreased from 151.00 Cr. (Mar 2025) to 141.00 Cr., marking a decrease of 10.00 Cr..
- For Total Assets, as of Sep 2025, the value is 260.00 Cr.. The value appears to be declining and may need further review. It has decreased from 270.00 Cr. (Mar 2025) to 260.00 Cr., marking a decrease of 10.00 Cr..
Notably, the Reserves (71.00 Cr.) exceed the Borrowings (47.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -49.00 | -50.00 | -60.00 | -45.00 | -55.00 | -34.00 | -34.00 | -30.00 | -2.00 | -37.00 | -40.00 | -42.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 95 | 74 | 83 | 79 | 100 | 84 | 79 | 87 | 52 | 59 | 55 | 82 |
| Inventory Days | 95 | 86 | 72 | 66 | 75 | 61 | 76 | 58 | 48 | 62 | 58 | 75 |
| Days Payable | 178 | 139 | 135 | 138 | 207 | 191 | 184 | 184 | 151 | 131 | 133 | 158 |
| Cash Conversion Cycle | 12 | 22 | 20 | 6 | -32 | -46 | -29 | -39 | -50 | -10 | -19 | -2 |
| Working Capital Days | -347 | -318 | -156 | -185 | -187 | -190 | -140 | -88 | -25 | -43 | -35 | -25 |
| ROCE % | -16% | -19% | -44% | -1% | -5% | 16% | 25% | 18% | 34% | 11% | 7% | 9% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.64 | 0.74 | 1.45 | 6.16 | 3.83 |
| Diluted EPS (Rs.) | 0.64 | 0.74 | 1.45 | 6.16 | 3.83 |
| Cash EPS (Rs.) | 1.08 | 1.56 | 1.94 | 5.63 | 2.96 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 18.27 | 17.90 | 17.09 | 15.64 | 9.64 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 18.27 | 17.90 | 17.09 | 15.64 | 9.64 |
| Revenue From Operations / Share (Rs.) | 25.60 | 22.65 | 22.22 | 25.67 | 21.35 |
| PBDIT / Share (Rs.) | 2.54 | 2.18 | 2.75 | 8.73 | 3.76 |
| PBIT / Share (Rs.) | 2.02 | 1.71 | 2.39 | 8.43 | 3.44 |
| PBT / Share (Rs.) | 0.54 | 1.22 | 2.07 | 6.23 | 3.06 |
| Net Profit / Share (Rs.) | 0.56 | 1.10 | 1.58 | 5.32 | 2.64 |
| NP After MI And SOA / Share (Rs.) | 0.64 | 0.74 | 1.45 | 6.16 | 3.83 |
| PBDIT Margin (%) | 9.92 | 9.61 | 12.36 | 34.00 | 17.59 |
| PBIT Margin (%) | 7.87 | 7.55 | 10.74 | 32.82 | 16.11 |
| PBT Margin (%) | 2.13 | 5.39 | 9.31 | 24.28 | 14.31 |
| Net Profit Margin (%) | 2.18 | 4.83 | 7.13 | 20.73 | 12.36 |
| NP After MI And SOA Margin (%) | 2.51 | 3.27 | 6.51 | 23.99 | 17.93 |
| Return on Networth / Equity (%) | 3.52 | 4.14 | 8.47 | 39.39 | 39.72 |
| Return on Capital Employeed (%) | 10.33 | 8.86 | 12.15 | 51.65 | 32.36 |
| Return On Assets (%) | 1.82 | 2.27 | 4.51 | 20.48 | 13.97 |
| Long Term Debt / Equity (X) | 0.05 | 0.06 | 0.13 | 0.02 | 0.07 |
| Total Debt / Equity (X) | 0.34 | 0.32 | 0.30 | 0.21 | 0.35 |
| Asset Turnover Ratio (%) | 0.75 | 0.69 | 0.71 | 0.00 | 0.00 |
| Current Ratio (X) | 0.98 | 1.16 | 1.23 | 1.14 | 0.93 |
| Quick Ratio (X) | 0.78 | 1.00 | 1.04 | 0.99 | 0.81 |
| Inventory Turnover Ratio (X) | 9.81 | 0.90 | 0.80 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 4.56 | 4.44 | 8.64 | 39.34 | 9.76 |
| Interest Coverage Ratio (Post Tax) (X) | 3.65 | 3.23 | 5.98 | 33.88 | 7.86 |
| Enterprise Value (Cr.) | 305.67 | 360.72 | 169.24 | 264.81 | 129.80 |
| EV / Net Operating Revenue (X) | 1.56 | 2.08 | 0.99 | 1.35 | 0.79 |
| EV / EBITDA (X) | 15.70 | 21.61 | 8.04 | 3.96 | 4.51 |
| MarketCap / Net Operating Revenue (X) | 1.37 | 2.01 | 0.92 | 1.36 | 0.82 |
| Price / BV (X) | 1.92 | 2.54 | 1.20 | 2.23 | 1.83 |
| Price / Net Operating Revenue (X) | 1.37 | 2.01 | 0.92 | 1.36 | 0.82 |
| EarningsYield | 0.01 | 0.01 | 0.07 | 0.17 | 0.21 |
After reviewing the key financial ratios for Ambalal Sarabhai Enterprises Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.64. This value is below the healthy minimum of 5. It has decreased from 0.74 (Mar 24) to 0.64, marking a decrease of 0.10.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.64. This value is below the healthy minimum of 5. It has decreased from 0.74 (Mar 24) to 0.64, marking a decrease of 0.10.
- For Cash EPS (Rs.), as of Mar 25, the value is 1.08. This value is below the healthy minimum of 3. It has decreased from 1.56 (Mar 24) to 1.08, marking a decrease of 0.48.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 18.27. It has increased from 17.90 (Mar 24) to 18.27, marking an increase of 0.37.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 18.27. It has increased from 17.90 (Mar 24) to 18.27, marking an increase of 0.37.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 25.60. It has increased from 22.65 (Mar 24) to 25.60, marking an increase of 2.95.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 2.54. This value is within the healthy range. It has increased from 2.18 (Mar 24) to 2.54, marking an increase of 0.36.
- For PBIT / Share (Rs.), as of Mar 25, the value is 2.02. This value is within the healthy range. It has increased from 1.71 (Mar 24) to 2.02, marking an increase of 0.31.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.54. This value is within the healthy range. It has decreased from 1.22 (Mar 24) to 0.54, marking a decrease of 0.68.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.56. This value is below the healthy minimum of 2. It has decreased from 1.10 (Mar 24) to 0.56, marking a decrease of 0.54.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 0.64. This value is below the healthy minimum of 2. It has decreased from 0.74 (Mar 24) to 0.64, marking a decrease of 0.10.
- For PBDIT Margin (%), as of Mar 25, the value is 9.92. This value is below the healthy minimum of 10. It has increased from 9.61 (Mar 24) to 9.92, marking an increase of 0.31.
- For PBIT Margin (%), as of Mar 25, the value is 7.87. This value is below the healthy minimum of 10. It has increased from 7.55 (Mar 24) to 7.87, marking an increase of 0.32.
- For PBT Margin (%), as of Mar 25, the value is 2.13. This value is below the healthy minimum of 10. It has decreased from 5.39 (Mar 24) to 2.13, marking a decrease of 3.26.
- For Net Profit Margin (%), as of Mar 25, the value is 2.18. This value is below the healthy minimum of 5. It has decreased from 4.83 (Mar 24) to 2.18, marking a decrease of 2.65.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 2.51. This value is below the healthy minimum of 8. It has decreased from 3.27 (Mar 24) to 2.51, marking a decrease of 0.76.
- For Return on Networth / Equity (%), as of Mar 25, the value is 3.52. This value is below the healthy minimum of 15. It has decreased from 4.14 (Mar 24) to 3.52, marking a decrease of 0.62.
- For Return on Capital Employeed (%), as of Mar 25, the value is 10.33. This value is within the healthy range. It has increased from 8.86 (Mar 24) to 10.33, marking an increase of 1.47.
- For Return On Assets (%), as of Mar 25, the value is 1.82. This value is below the healthy minimum of 5. It has decreased from 2.27 (Mar 24) to 1.82, marking a decrease of 0.45.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 0.2. It has decreased from 0.06 (Mar 24) to 0.05, marking a decrease of 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.34. This value is within the healthy range. It has increased from 0.32 (Mar 24) to 0.34, marking an increase of 0.02.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.75. It has increased from 0.69 (Mar 24) to 0.75, marking an increase of 0.06.
- For Current Ratio (X), as of Mar 25, the value is 0.98. This value is below the healthy minimum of 1.5. It has decreased from 1.16 (Mar 24) to 0.98, marking a decrease of 0.18.
- For Quick Ratio (X), as of Mar 25, the value is 0.78. This value is below the healthy minimum of 1. It has decreased from 1.00 (Mar 24) to 0.78, marking a decrease of 0.22.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 9.81. This value exceeds the healthy maximum of 8. It has increased from 0.90 (Mar 24) to 9.81, marking an increase of 8.91.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 4.56. This value is within the healthy range. It has increased from 4.44 (Mar 24) to 4.56, marking an increase of 0.12.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 3.65. This value is within the healthy range. It has increased from 3.23 (Mar 24) to 3.65, marking an increase of 0.42.
- For Enterprise Value (Cr.), as of Mar 25, the value is 305.67. It has decreased from 360.72 (Mar 24) to 305.67, marking a decrease of 55.05.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.56. This value is within the healthy range. It has decreased from 2.08 (Mar 24) to 1.56, marking a decrease of 0.52.
- For EV / EBITDA (X), as of Mar 25, the value is 15.70. This value exceeds the healthy maximum of 15. It has decreased from 21.61 (Mar 24) to 15.70, marking a decrease of 5.91.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.37. This value is within the healthy range. It has decreased from 2.01 (Mar 24) to 1.37, marking a decrease of 0.64.
- For Price / BV (X), as of Mar 25, the value is 1.92. This value is within the healthy range. It has decreased from 2.54 (Mar 24) to 1.92, marking a decrease of 0.62.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.37. This value is within the healthy range. It has decreased from 2.01 (Mar 24) to 1.37, marking a decrease of 0.64.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Ambalal Sarabhai Enterprises Ltd:
- Net Profit Margin: 2.18%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 10.33% (Industry Average ROCE: 16.15%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 3.52% (Industry Average ROE: 14.71%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 3.65
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.78
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 14.2 (Industry average Stock P/E: 42.76)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.34
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 2.18%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Shanti Sadan, Mirzapur Road, Ahmedabad Gujarat 380001 | dsejpal@ase.life http://www.ase.life |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Kartikeya V Sarabhai | Executive Chairman |
| Mr. Mohal K Sarabhai | Managing Director |
| Ms. Chaula M Shastri | Whole Time Director |
| Dr. Pushpa Robin | Independent Director |
| Mr. Mayur Swadia | Independent Director |
| Mr. Satyen Dave | Independent Director |
| Mr. Brijesh Khandelwal | Independent Director |
| Mr. Govindprasad Namdeo | Independent Director |
| Mr. Ajay Mayor | Nominee Director |
| Mr. Bharatendu Jani | Nominee Director |
FAQ
What is the intrinsic value of Ambalal Sarabhai Enterprises Ltd?
Ambalal Sarabhai Enterprises Ltd's intrinsic value (as of 12 December 2025) is 13.90 which is 52.07% lower the current market price of 29.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 222 Cr. market cap, FY2025-2026 high/low of 65.0/26.0, reserves of ₹71 Cr, and liabilities of 260 Cr.
What is the Market Cap of Ambalal Sarabhai Enterprises Ltd?
The Market Cap of Ambalal Sarabhai Enterprises Ltd is 222 Cr..
What is the current Stock Price of Ambalal Sarabhai Enterprises Ltd as on 12 December 2025?
The current stock price of Ambalal Sarabhai Enterprises Ltd as on 12 December 2025 is 29.0.
What is the High / Low of Ambalal Sarabhai Enterprises Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Ambalal Sarabhai Enterprises Ltd stocks is 65.0/26.0.
What is the Stock P/E of Ambalal Sarabhai Enterprises Ltd?
The Stock P/E of Ambalal Sarabhai Enterprises Ltd is 14.2.
What is the Book Value of Ambalal Sarabhai Enterprises Ltd?
The Book Value of Ambalal Sarabhai Enterprises Ltd is 19.2.
What is the Dividend Yield of Ambalal Sarabhai Enterprises Ltd?
The Dividend Yield of Ambalal Sarabhai Enterprises Ltd is 0.00 %.
What is the ROCE of Ambalal Sarabhai Enterprises Ltd?
The ROCE of Ambalal Sarabhai Enterprises Ltd is 9.12 %.
What is the ROE of Ambalal Sarabhai Enterprises Ltd?
The ROE of Ambalal Sarabhai Enterprises Ltd is 6.25 %.
What is the Face Value of Ambalal Sarabhai Enterprises Ltd?
The Face Value of Ambalal Sarabhai Enterprises Ltd is 10.0.